Fresenius Medical Care AG ADR
FMS: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$75.00 | Ngjwh | Xkh |
Fresenius Medical Care Earnings: Strong Start to 2024 but No Change to Outlook or Fair Value Yet
Narrow-moat Fresenius Medical Care turned in strong first-quarter results but may have disappointed the market with its weak treatment trends and merely maintained 2024 outlook. Overall, our 2024 expectations remain at the high end of management's outlook, and we do not anticipate changing our fair value estimate, which remains well above recent trades.